Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
January 24, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
January 17, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
January 10, 2023 08:30 ET
|
Veru Inc.
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
KRONOS® AIR DISINFECTION TECHNOLOGY MANUFACTURER RECEIVES FDA 510(K) CLASS II MEDICAL DEVICE CLEARANCE FOR THE DESTRUCTION OF VIRUSES, BACTERIA, AND ALLERGENS.
January 10, 2023 06:18 ET
|
Kronos Advanced Technologies Inc.
Parkersburg, WV, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Parkersburg, WV January 10, 2023 /Globenewswire/ KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) ("KNOS" or the "Company"),...
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
January 09, 2023 15:34 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
January 09, 2023 06:00 ET
|
Ocugen
Study met both co-primary endpoints with robust immune responses COVAXIN™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the...
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
January 06, 2023 14:50 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Alphalyse and Bavarian Nordic A/S significantly shorten the time necessary to document HCP impurities in COVID-19 vaccine candidate for Phase 3 clinical trial – through world’s first MS-based HCP analysis under GMP conditions
January 03, 2023 07:53 ET
|
Alphalyse A/S
ODENSE, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Alphalyse has performed the world’s first GMP-certified mass spectrometry (MS)-based Host Cell Protein (HCP) analysis for product release testing...
The Association of American Physicians and Surgeons (AAPS) Supports Courts’ Authority over a Hospital that Denies Patients’ Access to a Common Treatment
December 23, 2022 13:28 ET
|
Association of American Physicians and Surgeons
TUCSON, Ariz., Dec. 23, 2022 (GLOBE NEWSWIRE) -- The Association of American Physicians and Surgeons (AAPS) has filed an amicus brief with the Wisconsin Supreme Court to urge it to reverse a 2-1...
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
December 22, 2022 12:10 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE FIRST TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, December 22, 2022, 6pm CET ...